Toggle Offcanvas
...
Global Government Tenders

Most trusted source for Tendering Opportunities and Business Intelligence since 2002

Specific Contract For The Supply Of The Briumvi 150Mg Drug (Active Ingredient Ublituximab), Through The Use Of The Sintel Sda Platform.

Fondazione IRCCS Istituto Neurologico Besta Italy has Released a tender for Specific Contract For The Supply Of The Briumvi 150Mg Drug (Active Ingredient Ublituximab), Through The Use Of The Sintel Sda Platform. in Healthcare and Medicine. The tender was released on Apr 04, 2025.

Country - Italy

Summary - Specific Contract For The Supply Of The Briumvi 150Mg Drug (Active Ingredient Ublituximab), Through The Use Of The Sintel Sda Platform.

Deadline - Apr 11, 2025

GT reference number - 106365828

Product classification - Medical equipments, pharmaceuticals and personal care products

Organization Details:

  Address - Italy

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 106365828

  Document Type - Tender Notices

Notice Details and Documents:

Description - notice_title: Specific Contract For The Supply Of The Briumvi 150Mg Drug (Active Ingredient Ublituximab), Through The Use Of The Sintel Sda Platform.local title:: Appalto specifico per la fornitura del farmaco BRIUMVI 150mg (principio attivo UBLITUXI MAB), mediante l’utilizzo della piattaforma Sintel SDA.Contract Type: : SupplyNet Budget Euro: : 75888.54Net Budget LC: : 75888.54Tender URL: : https://www.ariaspa.it/wps/portal/Aria/Home/bandi-convenzioni/e-procurement/strumenti-di-supporto/guide-e-manuali est_amount: 75888.54

Gt Ref Id - 106365828

Deadline - Apr 11, 2025

Share share

Similar Tenders :

Create Account

Why Us

3,00,000 +

Users

190 +

Countries Covered

5,00,000 +

Agencies Tracked

50,000 +

Notices Daily

90 Million +

Database